Abelson Non-Tyrosine Kinase Compounds for the Treatment of Neurodegenerative Diseases

A compound of Formula (I),

• or salt thereof, wherein RA is a halogen or a C2-C4 alkyl, which may be saturated or unsaturated, branched or cyclic and RA is optionally substituted with R10;
• RB and RC are individually and independently selected from a H, hydroxyl, a C2-C4 alkyl, which may be saturated or unsaturated, branched or cyclic, halogen, nitro, cyano, hydroxy, amino, formyl, carbamoyl, alkoxy, acetyl, carbocyclyl, aryl, or heterocyclyl and RB and RC are each optionally substituted with R10;
• Ring Y is a 5 or 6 membered carbocyclyl, aryl, or heterocyclyl;
• Ring Z is a 5 or 6 membered carbocyclyl, aryl, or heterocyclyl or is absent;
• and
• R10 is a halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl, or heterocyclyl.